On May 4, 2010, Peter Gasser, M.D. submitted an amendment to our Swiss LSD/end-of-life anxiety study to his Ethics Committee (EC). The EC will meet on May 25 to evaluate the amendment. The amendment requests …
The eighth subject has been enrolled in the MAPS-sponsored clinical trial evaluating LSD to alleviate anxiety associated with a life-threatening illness. The subject has completed the screening process …
SwissMedic, Switzerlands equivalent of the FDA, permitted our LSD/end-of-life study to proceed for another year. We are pleased with the outcomes of the study so far. Recruitment has been challenging, …
The sixth subject out of an eventual 12 subjects has been enrolled in our LSD/end-of-life-anxiety study.
“Inside LSD” Broadcast on National Geographic Explorer 11/3/09 — Host a Viewing Party to Build Community and Increase MAPS Membership With Our Matching Grant Program! On Tuesday, November …
LSDs long strange trip back into the lab By Erin Allday, Chronicle Staff Writer Sunday, September 27, 2009 From: http://www.sfgate.com/cgi-bin/article.cgi?file=/c/a/2009/09/27/MNEN19SNGD.DTL#ixzz0SR57CLR1 …
We submitted to the FDA the annual report about our LSD research. Annual reports are designed to give the FDA an overview of new developments. We reported on the progress from the first 4 subjects out …
Swiss LSD/End-of-Life Study Receives $25,695 donation: On April 8, Robert Barnhart generously donated $25,695 to MAPS for our Swiss LSD/End-of-Life study. Robert has now donated over $100,000 to this study, …
Investigator: Peter Gasser MD Sponsor: MAPS Contact: Peter Gasser, MD This research will study the safety and efficacy of LSD-assisted psychotherapy in reducing anxiety arising from diagnosis with a serious …
Dr. Peter Gasser, the Principal Investigator (PI) for the MAPS-sponsored LSD/end-of-life anxiety study, issued the first Annual Report discussing the progress weve made in this last year. Were making gradual …
Principal Investigator Peter Gasser MD has enrolled 4 patients in his Swiss LSD/end-of-life anxiety study. On November 3, the second of the patients had an LSD session. On Friday, November 7, MAPS transferred …
The FDA issued a letter saying that we had successfully resolved all the outstanding issues in our Investigative New Drug application (#101,825) to evaluate LSD-assisted psychotherapy in our Swiss end-of-life/anxiety …
